bluebird bio, Inc. (BLUE)
Largest Insider Buys in Sector
BLUE Stock Price History Chart
BLUE Stock Performance
About bluebird bio, Inc.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of …
Insider Activity of bluebird bio, Inc.
Over the last 12 months, insiders at bluebird bio, Inc. have bought $0 and sold $64,965 worth of bluebird bio, Inc. stock.
On average, over the past 5 years, insiders at bluebird bio, Inc. have bought $0 and sold $909,852 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 19,364 shares for transaction amount of $1M was made by Leschly Nick (President and CEO) on 2015‑12‑08.
List of Insider Buy and Sell Transactions, bluebird bio, Inc.
| 2024-12-10 | Sale | President and CEO | 971 0.0005% | $0.42 | $405 | -6.46% | ||
| 2024-12-10 | Sale | Chief Medical Officer | 2,824 0.0014% | $0.42 | $1,178 | -6.46% | ||
| 2024-09-30 | Sale | President and CEO | 34,780 0.0189% | $0.53 | $18,270 | -13.23% | ||
| 2024-09-30 | Sale | See Remarks | 1,006 0.0005% | $0.53 | $529 | -13.23% | ||
| 2024-06-03 | Sale | See Remarks | 3,834 0.002% | $0.97 | $3,726 | -41.05% | ||
| 2024-03-04 | Sale | President and CEO | 6,095 0.0031% | $1.53 | $9,311 | -40.49% | ||
| 2024-03-04 | Sale | See Remarks | 4,573 0.0023% | $1.53 | $6,986 | -40.49% | ||
| 2024-03-01 | Sale | Chief Medical Officer | 6,770 0.0034% | $1.53 | $10,342 | -41.76% | ||
| 2024-02-05 | Sale | President and CEO | 1,879 0.0008% | $0.90 | $1,696 | +3.20% | ||
| 2024-02-05 | Sale | See Remarks | 2,714 0.0012% | $0.90 | $2,449 | +3.20% | ||
| 2024-02-05 | Sale | Chief Business & Legal Officer | 5,217 0.0023% | $0.90 | $4,708 | +3.20% | ||
| 2024-01-05 | Sale | President and CEO | 3,162 0.0016% | $1.43 | $4,520 | -32.92% | ||
| 2024-01-05 | Sale | Chief Medical Officer | 597 0.0003% | $1.42 | $845 | -32.92% | ||
| 2023-12-06 | Sale | Chief Financial Officer | 4,526 0.0039% | $4.52 | $20,437 | -79.64% | ||
| 2023-11-03 | Sale | President and CEO | 807 0.0007% | $3.17 | $2,555 | -70.40% | ||
| 2023-11-02 | Sale | Chief Medical Officer | 2,343 0.0021% | $2.98 | $6,975 | -66.23% | ||
| 2023-09-05 | Sale | See Remarks | 922 0.0009% | $3.79 | $3,493 | -66.98% | ||
| 2023-08-10 | Sale | President and CEO | 16,929 0.0168% | $3.54 | $59,956 | -59.47% | ||
| 2023-06-02 | Sale | See Remarks | 4,130 0.0039% | $3.50 | $14,451 | -20.52% | ||
| 2023-01-11 | Sale | director | 4,290 0.0041% | $7.80 | $33,480 | -55.56% |
Insider Historical Profitability
| Leschly Nick | director | 280149 2.8815% | $8.50 | 1 | 49 | <0.0001% |
| MARAGANORE JOHN | director | 5843 0.0601% | $8.50 | 2 | 4 | +99.03% |
| Schenkein David P | director | 3176 0.0327% | $8.50 | 1 | 2 | +30.47% |
Institutional Investor Ownership
| BlackRock | $19.43M | 7.97 | 15.18M | +68.97% | +$7.93M | <0.0001 | |
| The Vanguard Group | $13.44M | 5.52 | 10.5M | +19.64% | +$2.21M | <0.0001 | |
| Granahan Investment Management | $9.87M | 4.05 | 7.71M | -4.53% | -$468,515.83 | 0.35 | |
| Ameriprise Financial | $8.18M | 3.36 | 6.39M | +131.96% | +$4.65M | <0.01 | |
| Millennium Management LLC | $7.99M | 3.28 | 6.24M | +82.78% | +$3.62M | 0.01 |